CureVac N.V. (NASDAQ:CVAC) Given Consensus Recommendation of “Hold” by Analysts

by · The Cerbat Gem

Shares of CureVac N.V. (NASDAQ:CVAC – Get Free Report) have received an average rating of “Hold” from the six analysts that are currently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and one has given a buy rating to the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $6.8333.

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of CureVac in a report on Tuesday, December 16th.

View Our Latest Report on CVAC

Institutional Trading of CureVac

Several institutional investors have recently added to or reduced their stakes in the business. Caitong International Asset Management Co. Ltd raised its stake in shares of CureVac by 354.8% in the second quarter. Caitong International Asset Management Co. Ltd now owns 5,608 shares of the company’s stock worth $30,000 after purchasing an additional 4,375 shares during the last quarter. Headlands Technologies LLC bought a new stake in CureVac in the 2nd quarter worth about $35,000. Integrated Wealth Concepts LLC grew its stake in shares of CureVac by 25.0% in the first quarter. Integrated Wealth Concepts LLC now owns 15,000 shares of the company’s stock worth $42,000 after acquiring an additional 3,000 shares during the period. Kathmere Capital Management LLC bought a new position in shares of CureVac during the 2nd quarter valued at $60,000. Finally, L2 Asset Management LLC bought a new position in shares of CureVac during the 2nd quarter valued at $70,000. 17.26% of the stock is currently owned by hedge funds and other institutional investors.

CureVac Stock Performance

CureVac stock opened at $4.21 on Wednesday. The stock’s 50 day moving average is $5.15 and its 200 day moving average is $5.30. The company has a market capitalization of $944.46 million, a P/E ratio of 5.85 and a beta of 1.77. CureVac has a twelve month low of $4.00 and a twelve month high of $4.36. The company has a quick ratio of 3.69, a current ratio of 3.70 and a debt-to-equity ratio of 0.03.

CureVac (NASDAQ:CVAC – Get Free Report) last released its earnings results on Monday, November 24th. The company reported ($0.10) EPS for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.07. The firm had revenue of $63.53 million for the quarter, compared to analysts’ expectations of $21.40 million. CureVac had a negative return on equity of 23.03% and a net margin of 199.92%. On average, equities research analysts predict that CureVac will post 0.72 earnings per share for the current fiscal year.

About CureVac

(Get Free Report)

CureVac N.V. is a clinical-stage biopharmaceutical company that specializes in the research, development and commercialization of messenger RNA (mRNA)-based medicines and vaccines. Leveraging its proprietary mRNA platform, the company seeks to harness the body’s natural protein production processes to address a range of diseases, with particular emphasis on prophylactic vaccines for infectious diseases as well as therapeutic candidates in oncology. CureVac’s technology is designed to deliver optimized mRNA sequences for in vivo expression, aiming to improve stability, translational efficiency and immunogenicity compared with conventional approaches.

Founded in 2000 and headquartered in Tübingen, Germany, CureVac has built a pipeline spanning early- to late-stage clinical programs.

Read More